xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05967455</url>
    </required_header>
    <id_info>
      <org_study_id>2023-01-UMU</org_study_id>
      <nct_id>NCT05967455</nct_id>
    </id_info>
    <brief_title>Homologous Re-infection With Dengue 1 or Dengue 3</brief_title>
    <official_title>Phase One, Open Label, Homologous Reinfection With Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) or Dengue-3-Virus-Live Virus Human Challenge (DENV-3-LVHC) Virus Strains</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>State University of New York - Upstate Medical University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>U.S. Army Medical Research and Development Command</agency>
        <agency_class>U.S. Fed</agency_class>
      </collaborator>
      <collaborator>
        <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
        <agency_class>U.S. Fed</agency_class>
      </collaborator>
    </sponsors>
    <source>State University of New York - Upstate Medical University</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Previous studies with one dengue infection in a controlled environment at Upstate generated&#xD;
        data that has been important in understanding the clinical signs and symptoms and how a&#xD;
        person's body reacts to dengue infection over time. This has helped investigators compare&#xD;
        what is seen in the clinic to what is seen in areas where dengue is prevalent. The&#xD;
        investigators want to collect similar information when a person gets the same dengue twice in&#xD;
        a controlled environment with the hope that this will lead them to a better understanding of&#xD;
        the disease.&#xD;
  &#xD;
        New participants&#xD;
  &#xD;
          -  will receive one inoculation of dengue and then return to the clinic or be contacted by&#xD;
             phone over 6 months;&#xD;
  &#xD;
          -  will receive a second inoculation after 6 months and return to the clinic or be&#xD;
             contacted by phone for one more month;&#xD;
  &#xD;
          -  will collect saliva at home;&#xD;
  &#xD;
          -  will allow the study team to collect blood and saliva at the clinic visits.&#xD;
  &#xD;
        Participants who have been in previous dengue inoculation studies at SUNY Upstate&#xD;
  &#xD;
          -  will receive one inoculation of dengue and then return to the clinic or be contacted by&#xD;
             phone over 3 months;&#xD;
  &#xD;
          -  will collect saliva at home;&#xD;
  &#xD;
          -  will allow the study team to collect blood and saliva at the clinic visits.&#xD;
  &#xD;
        All participants will be seen in the clinic every other day for the first three weeks after&#xD;
        any inoculation.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The purpose of this study is to explore the clinical, virologic, and immunologic response of&#xD;
        subjects following primary controlled dengue infection or following controlled homologous&#xD;
        dengue reinfection.&#xD;
  &#xD;
        SUNY Upstate Medical University completed three Dengue Human Infection Model studies, two&#xD;
        with dengue 1 (DENV-1-LVHC), NCT 02372175 and NCT 03869060, and one with dengue 3&#xD;
        (DENV-3-LVHC), NCT 04298138 and investigators gained incredible knowledge about primary&#xD;
        dengue infection. The investigators are moving to the next step in acquiring knowledge about&#xD;
        the kinetics of homologous secondary infection in a controlled setting in this study. People&#xD;
        who acquire natural dengue infection and who are subsequently infected by the same serotype&#xD;
        are thought to have lifelong protection to that serotype.&#xD;
  &#xD;
        Investigators will recruit up to 10 naive participants and infect them with either&#xD;
        DENV-1-LVHC or DENV-3-LVHC with the same dose of virus as in previous studies. These&#xD;
        participants will be followed over 6 months and reinfected with the same serotype originally&#xD;
        received, i.e. homologous reinfection, and followed for another month through the viremic&#xD;
        phase. Investigators will also recruit up to 10 participants who received either DENV-1-LVHC&#xD;
        or DENV-3-LVHC in previous studies. These participants will be reinfected with the same&#xD;
        serotype that was previously received and followed for 3 months. Investigators intend to&#xD;
        collect similar information about the kinetics of homologous secondary infection as was&#xD;
        collected in the studies following primary infection.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 2023</start_date>
    <completion_date type="Anticipated">April 2024</completion_date>
    <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Non-Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Other</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Occurrence of Solicited Injection Site Symptoms</measure>
      <time_frame>6 days post virus inoculation</time_frame>
      <description>Number of solicited symptoms</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Intensity of Solicited Injection Site Symptoms</measure>
      <time_frame>6 days post virus inoculation</time_frame>
      <description>Graded according to FDA Tables for Clinical Abnormalities: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe), Grade 4 (Potentially life threatening)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Duration of Solicited Injection Site Symptoms</measure>
      <time_frame>6 days post virus inoculation</time_frame>
      <description>Number of days per symptom</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Occurrence of Solicited Systemic Symptoms</measure>
      <time_frame>20 day post primary infection for cohorts 1 and 2 and 20 days post reinfection, all cohorts</time_frame>
      <description>Number of solicited symptoms</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Intensity of Solicited Systemic Symptoms</measure>
      <time_frame>20 day post primary infection, cohorts 1 and 2 and 20 days post reinfection, all cohorts</time_frame>
      <description>Graded according to FDA Tables for Clinical Abnormalities: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe), Grade 4 (Potentially life threatening)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Duration of Solicited Systemic Symptoms</measure>
      <time_frame>20 day post primary infection, cohorts 1 and 2 and 20 days post reinfection, all cohorts</time_frame>
      <description>Number of days per symptom</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Occurrence of Unsolicited Systemic Symptoms</measure>
      <time_frame>28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts</time_frame>
      <description>Number of unsolicited symptom</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Intensity of Unsolicited Systemic Symptoms</measure>
      <time_frame>28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts</time_frame>
      <description>Graded according to FDA Tables for Clinical Abnormalities: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe), Grade 4 (Potentially life threatening)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Duration of Unsolicited Systemic Symptoms</measure>
      <time_frame>28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts</time_frame>
      <description>Number of days per symptom</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Number of Abnormal Laboratory Measurements</measure>
      <time_frame>28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts</time_frame>
      <description>Total number of all abnormal labs</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Intensity of Abnormal Laboratory Measurements</measure>
      <time_frame>28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts</time_frame>
      <description>Graded according to SUNY Upstate clinical laboratory normals and FDA Tables for Laboratory Abnormalities: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe), Grade 4 (Potentially life threatening)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Duration of Abnormal Laboratory Measurements</measure>
      <time_frame>28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts</time_frame>
      <description>Number of days of abnormal labs</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Number of Serious Adverse Events</measure>
      <time_frame>6 months post primary infection, cohorts 1 and 2</time_frame>
      <description>Total number</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Number of Serious Adverse Events</measure>
      <time_frame>28 days post reinfection, cohorts 1 and 2</time_frame>
      <description>Total number</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Number of Serious Adverse Events</measure>
      <time_frame>90 days post reinfection, cohorts 3 and 4</time_frame>
      <description>Total number</description>
    </primary_outcome>
    <number_of_arms>4</number_of_arms>
    <enrollment type="Anticipated">20</enrollment>
    <condition>Dengue</condition>
    <arm_group>
      <arm_group_label>Cohort 1 Naive DENV1</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Dengue-1-Virus-Live-Virus-Human-Challenge (DENV-1-LVHC), two doses (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1 and day 180.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Cohort 2 Naive DENV3</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Dengue-3-Virus-Live-Virus-Human-Challenge (DENV-3-LVHC), two doses (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1 and day 180.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Cohort 3 Returning DENV1</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Dengue-1-Virus-Live-Virus-Human-Challenge (DENV-1-LVHC), single dose (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Cohort 4 Returning DENV3</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Dengue-3-Virus-Live-Virus-Human-Challenge (DENV-3-LVHC), single dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1.</description>
    </arm_group>
    <intervention>
      <intervention_type>Biological</intervention_type>
      <intervention_name>Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)</intervention_name>
      <description>Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5</description>
      <arm_group_label>Cohort 1 Naive DENV1</arm_group_label>
      <arm_group_label>Cohort 3 Returning DENV1</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Biological</intervention_type>
      <intervention_name>Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)</intervention_name>
      <description>Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489</description>
      <arm_group_label>Cohort 2 Naive DENV3</arm_group_label>
      <arm_group_label>Cohort 4 Returning DENV3</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Age 18-55 at the time of consent&#xD;
  &#xD;
            2. Ability and willingness to sign informed consent&#xD;
  &#xD;
            3. Passing score on comprehension test of at least 75%, with up to 3 attempts&#xD;
  &#xD;
            4. Available for the study period&#xD;
  &#xD;
            5. Willing to use contraception for the duration of the study (birth control pills or&#xD;
               patches, intrauterine device (IUD), Depo-Provera, implantable birth control (implants&#xD;
               of levonorgestrel), estrogenic vaginal ring, tubal ligation, vasectomy of the sole&#xD;
               male partner, male condom combined with a vaginal spermicide (foam, gel, film, cream,&#xD;
               or suppository), male condom combined with a female diaphragm, either with or without&#xD;
               vaginal spermicide, partner in a homosexual relationship, abstinence)&#xD;
  &#xD;
            6. Provide consent for release of medical history records from primary care physician,&#xD;
               college or university, urgent care or emergency room visit&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Female: pregnant or lactating&#xD;
  &#xD;
            2. Heavy menstrual bleeding within the last 6 months- menstrual periods lasting longer&#xD;
               than 6 days or requiring 5 or more pads or tampons per day, endometriosis or uterine&#xD;
               scarring&#xD;
  &#xD;
            3. Women who intend to become pregnant or men who intend to father a child during the&#xD;
               study period (approximately 209 days for Cohorts 1 and 2 and approximately 91 days for&#xD;
               Cohorts 3 and 4)&#xD;
  &#xD;
            4. Blood tests confirming infection with human immunodeficiency virus- 1 (HIV-1),&#xD;
               hepatitis C, hepatitis B (assessed by HbsAg) virus&#xD;
  &#xD;
            5. Positive antibodies to dengue (cohorts 1 and 2). If the subject has previously&#xD;
               screened negative for dengue in the last 12 months and has not traveled to an endemic&#xD;
               area. The results of the previous screening will be used.&#xD;
  &#xD;
            6. Any history of dengue infection or dengue vaccination (licensed or experimental)&#xD;
               (cohorts 1 and 2); or planned dengue vaccination during the study period (all cohorts)&#xD;
  &#xD;
            7. Recent (in the past 4 weeks) travel to any dengue endemic area or travel to a country&#xD;
               with risk of yellow fever or Japanese encephalitis transmission&#xD;
  &#xD;
            8. Positive urine screen for cocaine, amphetamines, opiates or methadone&#xD;
  &#xD;
            9. Currently taking anti-coagulant medication, aspirin or non-steroidal anti-inflammatory&#xD;
               drugs (NSAIDs)&#xD;
  &#xD;
           10. Active diabetes, active peptic ulcer disease (PUD), chronic obstructive pulmonary&#xD;
               disease (COPD), coronary artery disease (CAD)&#xD;
  &#xD;
           11. Known or suspected congenital or acquired immunodeficiency; or receipt of&#xD;
               immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or&#xD;
               long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2&#xD;
               consecutive weeks within the past 3 months)&#xD;
  &#xD;
           12. Current, or a history of, auto-immune disease other than well controlled Hashimoto's&#xD;
               thyroiditis&#xD;
  &#xD;
           13. History of Guillain-Barré syndrome (GBS)&#xD;
  &#xD;
           14. Diagnosis with Bipolar Disorder or Schizophrenia, hospitalization in the past year for&#xD;
               a mental health disorder, or any other psychiatric condition, which in the opinion of&#xD;
               the investigator prevents the subject from participating in the study.&#xD;
  &#xD;
           15. Hives, shortness of breath, swelling of the lips or throat, or hospitalization related&#xD;
               to a previous vaccination or an allergy to specific medications/animals for which&#xD;
               antigens may be in the virus preparations to include: shellfish allergy, fetal bovine&#xD;
               serum, L-glutamine, neomycin and streptomycin&#xD;
  &#xD;
           16. Chronic migraine headaches, defined as more than 15 headache days per month over a 3&#xD;
               month period of which more than 8 are migraines, in the absence of medication over use&#xD;
  &#xD;
           17. Planning to donate blood in the 1 year following inoculation with dengue&#xD;
  &#xD;
           18. Recent blood donation within prior 14 days of inoculation&#xD;
  &#xD;
           19. Receipt of blood products or antibodies within 56 days of inoculation or during the&#xD;
               study period&#xD;
  &#xD;
           20. Planned travel during the study period (approximately 210 days for Cohorts 1 and 2 and&#xD;
               approximately 91 days for Cohorts 3 and 4) which would interfere with the ability to&#xD;
               complete all study visits&#xD;
  &#xD;
           21. Subjects with the following grade 2 or greater lab abnormalities: Creatinine; ALT,&#xD;
               AST; Hemoglobin (females and males); WBC; Platelets; PT; PTT; Fibrinogen&#xD;
  &#xD;
           22. Any laboratory abnormalities prior to inoculation that are considered by the&#xD;
               investigator to be clinically significant in addition those listed above&#xD;
  &#xD;
           23. Significant screening physical examination abnormalities or chronic medical condition&#xD;
               that in the opinion of the investigator may impact subject safety&#xD;
  &#xD;
           24. Participation (active or follow-up phase) or planned participation in another vaccine,&#xD;
               drug, or medical device in the 4 weeks prior to this trial or during the trial&#xD;
  &#xD;
           25. Recent or scheduled receipt of any vaccine 4 weeks prior to or after virus inoculation&#xD;
  &#xD;
           26. Beliefs that bar the administration of blood products or transfusions&#xD;
  &#xD;
           27. Clinician discretion&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>55 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Stephen J Thomas, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>State University of New York - Upstate Medical University</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Keely Terrillion</last_name>
      <phone>315-464-9869</phone>
      <email>Trials@upstate.edu</email>
    </overall_contact>
    <location>
      <facility>
        <name>State University of New York, Upstate Medical University (SUNY-UMU)</name>
        <address>
          <city>Syracuse</city>
          <state>New York</state>
          <zip>13210</zip>
          <country>United States</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <results_reference>
      <citation>Endy TP, Wang D, Polhemus ME, Jarman RG, Jasper LE, Gromowski G, Lin L, De La Barra RA, Friberg H, Currier JR, Abbott M, Ware L, Klick M, Paolino KM, Blair DC, Eckels K, Rutvisuttinunt W, Thomas SJ. A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain. J Infect Dis. 2021 Feb 3;223(2):258-267. doi: 10.1093/infdis/jiaa351.</citation>
      <PMID>32572470</PMID>
    </results_reference>
    <results_reference>
      <citation>Waickman AT, Lu JQ, Fang H, Waldran MJ, Gebo C, Currier JR, Ware L, Van Wesenbeeck L, Verpoorten N, Lenz O, Tambuyzer L, Herrera-Taracena G, Van Loock M, Endy TP, Thomas SJ. Evolution of inflammation and immunity in a dengue virus 1 human infection model. Sci Transl Med. 2022 Oct 26;14(668):eabo5019. doi: 10.1126/scitranslmed.abo5019. Epub 2022 Oct 26.</citation>
      <PMID>36288280</PMID>
    </results_reference>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 21, 2023</study_first_submitted>
    <study_first_submitted_qc>July 28, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 1, 2023</study_first_posted>
    <last_update_submitted>July 28, 2023</last_update_submitted>
    <last_update_submitted_qc>July 28, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Dengue</keyword>
    <keyword>Flavivirus Infections</keyword>
    <keyword>Virus Diseases</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Dengue</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05967455
  org study id: 2023-01-UMU
  nct id: NCT05967455
  lead sponsor: 
  collaborator: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  Previous studies with one dengue infection in a controlled environment at Upstate generated
        data that has been important in understanding the clinical signs and symptoms and how a
        person's body reacts to dengue infection over time. This has helped investigators compare
        what is seen in the clinic to what is seen in areas where dengue is prevalent. The
        investigators want to collect similar information when a person gets the same dengue twice in
        a controlled environment with the hope that this will lead them to a better understanding of
        the disease.
  
        New participants
  
          -  will receive one inoculation of dengue and then return to the clinic or be contacted by
             phone over 6 months;
  
          -  will receive a second inoculation after 6 months and return to the clinic or be
             contacted by phone for one more month;
  
          -  will collect saliva at home;
  
          -  will allow the study team to collect blood and saliva at the clinic visits.
  
        Participants who have been in previous dengue inoculation studies at SUNY Upstate
  
          -  will receive one inoculation of dengue and then return to the clinic or be contacted by
             phone over 3 months;
  
          -  will collect saliva at home;
  
          -  will allow the study team to collect blood and saliva at the clinic visits.
  
        All participants will be seen in the clinic every other day for the first three weeks after
        any inoculation.
  The purpose of this study is to explore the clinical, virologic, and immunologic response of
        subjects following primary controlled dengue infection or following controlled homologous
        dengue reinfection.
  
        SUNY Upstate Medical University completed three Dengue Human Infection Model studies, two
        with dengue 1 (DENV-1-LVHC), NCT 02372175 and NCT 03869060, and one with dengue 3
        (DENV-3-LVHC), NCT 04298138 and investigators gained incredible knowledge about primary
        dengue infection. The investigators are moving to the next step in acquiring knowledge about
        the kinetics of homologous secondary infection in a controlled setting in this study. People
        who acquire natural dengue infection and who are subsequently infected by the same serotype
        are thought to have lifelong protection to that serotype.
  
        Investigators will recruit up to 10 naive participants and infect them with either
        DENV-1-LVHC or DENV-3-LVHC with the same dose of virus as in previous studies. These
        participants will be followed over 6 months and reinfected with the same serotype originally
        received, i.e. homologous reinfection, and followed for another month through the viremic
        phase. Investigators will also recruit up to 10 participants who received either DENV-1-LVHC
        or DENV-3-LVHC in previous studies. These participants will be reinfected with the same
        serotype that was previously received and followed for 3 months. Investigators intend to
        collect similar information about the kinetics of homologous secondary infection as was
        collected in the studies following primary infection.
  allocation: Non-Randomized
  intervention model: Parallel Assignment
  primary purpose: Other
  masking: None (Open Label)
  measure: Occurrence of Solicited Injection Site Symptoms
  time frame: 6 days post virus inoculation
  description: Number of solicited symptoms
  measure: Intensity of Solicited Injection Site Symptoms
  time frame: 6 days post virus inoculation
  description: Graded according to FDA Tables for Clinical Abnormalities: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe), Grade 4 (Potentially life threatening)
  measure: Duration of Solicited Injection Site Symptoms
  time frame: 6 days post virus inoculation
  description: Number of days per symptom
  measure: Occurrence of Solicited Systemic Symptoms
  time frame: 20 day post primary infection for cohorts 1 and 2 and 20 days post reinfection, all cohorts
  description: Number of solicited symptoms
  measure: Intensity of Solicited Systemic Symptoms
  time frame: 20 day post primary infection, cohorts 1 and 2 and 20 days post reinfection, all cohorts
  description: Graded according to FDA Tables for Clinical Abnormalities: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe), Grade 4 (Potentially life threatening)
  measure: Duration of Solicited Systemic Symptoms
  time frame: 20 day post primary infection, cohorts 1 and 2 and 20 days post reinfection, all cohorts
  description: Number of days per symptom
  measure: Occurrence of Unsolicited Systemic Symptoms
  time frame: 28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts
  description: Number of unsolicited symptom
  measure: Intensity of Unsolicited Systemic Symptoms
  time frame: 28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts
  description: Graded according to FDA Tables for Clinical Abnormalities: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe), Grade 4 (Potentially life threatening)
  measure: Duration of Unsolicited Systemic Symptoms
  time frame: 28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts
  description: Number of days per symptom
  measure: Number of Abnormal Laboratory Measurements
  time frame: 28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts
  description: Total number of all abnormal labs
  measure: Intensity of Abnormal Laboratory Measurements
  time frame: 28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts
  description: Graded according to SUNY Upstate clinical laboratory normals and FDA Tables for Laboratory Abnormalities: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (severe), Grade 4 (Potentially life threatening)
  measure: Duration of Abnormal Laboratory Measurements
  time frame: 28 day post primary infection, cohorts 1 and 2 and 28 days post reinfection, all cohorts
  description: Number of days of abnormal labs
  measure: Number of Serious Adverse Events
  time frame: 6 months post primary infection, cohorts 1 and 2
  description: Total number
  measure: Number of Serious Adverse Events
  time frame: 28 days post reinfection, cohorts 1 and 2
  description: Total number
  measure: Number of Serious Adverse Events
  time frame: 90 days post reinfection, cohorts 3 and 4
  description: Total number
  arm group label: Cohort 1 Naive DENV1
  arm group type: Experimental
  description: Dengue-1-Virus-Live-Virus-Human-Challenge (DENV-1-LVHC), two doses (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1 and day 180.
  arm group label: Cohort 2 Naive DENV3
  arm group type: Experimental
  description: Dengue-3-Virus-Live-Virus-Human-Challenge (DENV-3-LVHC), two doses (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1 and day 180.
  arm group label: Cohort 3 Returning DENV1
  arm group type: Experimental
  description: Dengue-1-Virus-Live-Virus-Human-Challenge (DENV-1-LVHC), single dose (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1.
  arm group label: Cohort 4 Returning DENV3
  arm group type: Experimental
  description: Dengue-3-Virus-Live-Virus-Human-Challenge (DENV-3-LVHC), single dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1.
  intervention type: Biological
  intervention name: Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)
  description: Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
  arm group label: Cohort 1 Naive DENV1
  arm group label: Cohort 3 Returning DENV1
  intervention type: Biological
  intervention name: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
  description: Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489
  arm group label: Cohort 2 Naive DENV3
  arm group label: Cohort 4 Returning DENV3
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 55 Years
  healthy volunteers: Accepts Healthy Volunteers
  last name: Stephen J Thomas, MD
  role: Principal Investigator
  affiliation: State University of New York - Upstate Medical University
  last name: Keely Terrillion
  phone: 315-464-9869
  email: Trials@upstate.edu
  facility: 
  country: United States
  citation: Endy TP, Wang D, Polhemus ME, Jarman RG, Jasper LE, Gromowski G, Lin L, De La Barra RA, Friberg H, Currier JR, Abbott M, Ware L, Klick M, Paolino KM, Blair DC, Eckels K, Rutvisuttinunt W, Thomas SJ. A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain. J Infect Dis. 2021 Feb 3;223(2):258-267. doi: 10.1093/infdis/jiaa351.
  PMID: 32572470
  citation: Waickman AT, Lu JQ, Fang H, Waldran MJ, Gebo C, Currier JR, Ware L, Van Wesenbeeck L, Verpoorten N, Lenz O, Tambuyzer L, Herrera-Taracena G, Van Loock M, Endy TP, Thomas SJ. Evolution of inflammation and immunity in a dengue virus 1 human infection model. Sci Transl Med. 2022 Oct 26;14(668):eabo5019. doi: 10.1126/scitranslmed.abo5019. Epub 2022 Oct 26.
  PMID: 36288280
  responsible party type: Sponsor
  mesh term: Dengue
  sharing ipd: No